It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as "available" on the U.S. Food and Drug Administration's drug shortage list. The change in status comes nearly six months after Novo Nordisk,